4//SEC Filing
Venrock Healthcare Capital Partners III, L.P. 4
Accession 0001415889-25-003665
CIK 0001348911other
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 7:51 PM ET
Size
21.5 KB
Accession
0001415889-25-003665
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds) - Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds)
Transactions
- Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds) - Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds)
VHCP Management EG, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds) - Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds)
VHCP Management III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds) - Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds)
Shah Nimish P
10% Owner
Transactions
- Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds) - Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds)
VHCP Co-Investment Holdings III, LLC
10% Owner
Transactions
- Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds) - Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds) - Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds)
Koh Bong Y
10% Owner
Transactions
- Purchase
Common Stock
2025-02-11$9.18/sh+26,703$245,134→ 5,117,285 total(indirect: By Funds) - Purchase
Common Stock
2025-02-07$9.29/sh+73,649$684,199→ 5,086,445 total(indirect: By Funds) - Purchase
Common Stock
2025-02-10$9.14/sh+4,137$37,812→ 5,090,582 total(indirect: By Funds)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.15 to $9.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F2]Consists of (i) 1,104,278 shares held by Venrock Healthcare Capital Partners III, L.P. ("VHCP3"); (ii) 110,465 shares held by VHCP Co-Investment Holdings III,LLC ("VHCP Co-3"); and (iii) 3,871,702 shares held by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
- [F3]VHCP Management III, LLC ("VHCPM3") is the general partner of VHCP3 and the manager of VHCP Co-3 and may be deemed to beneficially own these securities. VHCP Management EG, LLC ("VHCPMEG") is the general partner of VHCPEG and may be deemed to beneficially own these securities. Bong Koh and Nimish Shah are the voting members of VHCPM3 and VHCPMEG and may be deemed to beneficially own these securities. Each of VHCPM3, VHCPMEG and Messrs. Koh and Shah expressly disclaims beneficial ownership over these securities except to the extent of its or his indirect pecuniary interest therein.
- [F4]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.11 to $9.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F5]Consists of (i) 1,104,993 shares held by VHCP3; (ii) 110,536 shares held by VHCP Co-3; and (iii) 3,875,053 shares held by VHCP EG.
- [F6]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $9.07 to $9.21 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F7]Consists of (i) 1,109,607 shares held by VHCP3; (ii) 110,998 shares held by VHCP Co-3; and (iii) 3,896,680 shares held by VHCP EG.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001738048
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 7:51 PM ET
- Size
- 21.5 KB